Losers: Chemours (CC) -35% after reporting FY results. Ironwood Pharmaceuticals (NASDAQ:IRWD) -29% after announcing positive topline results from Global Phase III Trial of Once-Weekly Apraglutide in ...
Source LinkLosers: Chemours (CC) -35% after reporting FY results. Ironwood Pharmaceuticals (NASDAQ:IRWD) -29% after announcing positive topline results from Global Phase III Trial of Once-Weekly Apraglutide in ...
Source Link
Comments